Proteus Digital Health, developer of wearable and ingestible sensor technology, and Otsuka Pharmaceutical, a global healthcare company based in Japan, have entered into an exclusive worldwide license and collaboration agreement to develop and commercialize a new category of medicines.

These new medicines will be based on Otsuka’s pharmaceutical products and Proteus’s digital health feedback system incorporating Proteus’s novel sensor-based technologies. The duo will develop commercial products in two defined therapeutic areas of high unmet medical need. Otsuka has also been granted a non-exclusive license to utilize Proteus technology in its clinical research and development activities.

Financial terms of the agreement were not disclosed.